Vyfemla Kit
Product Images NDC 68180-875

9 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Vyfemla (NDC 68180-875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 01)

Image 1 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 01)
Chemical structures of the active ingredients Norethindrone and Ethinyl Estradiol, displaying their molecular formulas and molecular weights. The Norethindrone structure is labeled with C20H26O2 and molecular weight 298.4. The Ethinyl Estradiol structure is labeled with C20H24O2 and molecular weight 296.40.*
FDA Label Image

Fig-2 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 02)

Fig-2 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 02)
A bar chart titled 'Circulatory Disease Mortality Rates per 100,000 Women-Years by Age, Smoking Status and Oral Contraceptive Use.' It shows mortality rates (number of deaths per 100,000 woman users) on the vertical axis and age groups (15-24, 25-34, 35-44, 45+) on the horizontal axis. The legend differentiates between ever-users and controls, among nonsmokers and smokers, using different shades of gray and black for the bars.*
FDA Label Image

Figure 2 (Risk of Breat Cancer with Combined Oral Contraceptive Use)

Figure 2 (Risk of Breat Cancer with Combined Oral Contraceptive Use)
A forest plot chart showing effect estimates (odds ratios/relative risks) with confidence intervals from various women's health studies conducted between 2002 and 2017. The studies are listed on the left with effect sizes plotted around a reference value of 1.0 on the horizontal axis.*
FDA Label Image

Image (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 04)

FDA Label Image

Fig-3 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 05)

Fig-3 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 05)
An instructional diagram showing a 28-day pill pack layout with four rows, each representing a week labeled Week 1 to Week 4. Days of the week are labeled Sunday through Saturday across the top, with arrows indicating the sequence to take the pills. A note at the top instructs Day-1 starters to align the day label strip with the first day of their period if it does not begin on Sunday.*
FDA Label Image

Image (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 06)

FDA Label Image

Fig-4 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 07)

Fig-4 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 07)
Label for Vyfemla tablets containing norethindrone and ethinyl estradiol, 0.4 mg / 0.035 mg strength. The label includes packaging instructions, storage conditions, a barcode, and a monthly self breast exam reminder. Manufacturer is Lupin Limited, India, and distributed by Lupin Pharmaceuticals, Inc., United States. The label features a 28-day pill calendar with days of the week for tracking dose schedule.*
FDA Label Image

Fig-5 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 08)

Fig-5 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 08)
Packaging label for Vyfemla tablets USP, containing norethindrone and ethinyl estradiol at strengths of 0.4 mg and 0.035 mg. The product is provided by Lupin Pharmaceuticals, Inc., in a blister pack of 28 tablets. The label includes prescription-only status and standard safety information about use as an oral contraceptive.*
FDA Label Image

Fig-6 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 09)

Fig-6 (C44722bd 9db7 4ea4 B150 7d514b1bc4f7 09)
Packaging label for Vyfemla 0.4 mg/0.035 mg tablets, containing norethindrone and ethinyl estradiol. The label shows it is distributed by Lupin Pharmaceuticals, Inc. and manufactured by Lupin Limited in India. The package contains 3 blisters of 28 tablets each and displays prescription-only status with the NDC 68180-875-73.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.